Human immunodeficiency virus type 1 (HIV-1) infection is characterized by a prolonged, but variable, disease course, and both viral and host factors have been proposed as determinants of the rate of disease progression. Several lines of evidence support the concept that the HIV-1-specific cell-mediated immune response plays a major role in controlling HIV-1 infection in vivo and that the success or failure of relevant HIV-1-specific effector mechanisms in controlling viral replication contributes directly to defining the course of HIV-1 disease. HIV-1-specific cytotoxic T lymphocytes (CTL) and T cell lines have been shown to inhibit HIV-1 replication in vitro [1, 2] . Several investigators have demonstrated the emergence of HIV-1-specific cellular immune responses during primary HIV-1 infection at or around the time at which HIV-1 plasma RNA levels peak and begin to decline [3] [4] [5] [6] . Furthermore, CD8 depletion in the simian immunodeficiency virus (SIV) model is temporally associated with an increase in plasma SIV RNA [7] . These CTL responses may be dependent, at least in part, on the presence of virus-specific proliferative (lymphoproliferative) responses in the CD4 cell population [8] . The putative relationship between HIV-1-specific immune responses and control of viral replication in vivo has led to a number of attempts to augment relevant immune effector mechanisms by immunization of HIV-1-infected individuals with vaccines derived from HIV-1 or its components (or both) [9] [10] [11] [12] [13] . Although these studies have demonstrated that certain HIV-1-specific immune responses can be induced or augmented by vaccination, there is no convincing evidence, to date, that these efforts have resulted in reduced viral replication or in changes in the rate of disease progression. This lack of evidence has led to the decreased interest in such trials over the past several years.
Recently, there has been increased interest in the investigation of therapeutic interventions that might augment relevant HIV-1-specific immune responses. This renewed interest has stemmed from the realization that prior failures in this area might be due, at least in part, to the attempt to induce HIV-1-specific immune responses in the presence of substantial residual viral replication. With the advent of more potent antiretroviral chemotherapy, broad improvements in immune response parameters are observed in a substantial fraction of patients [14] [15] [16] . Thus, larger reductions in viral replication provide an opportunity to attempt augmentation of virus-specific immunity in the absence of high levels of HIV-1 that might be expected to interfere with the development of these responses [17] . With the realization that virus eradication is a more elusive goal than thought several years ago and the implication that antiretroviral chemotherapy is now probably a life-long undertaking, interest in therapeutic vaccination has reemerged, with the hope that augmentation of virus-specific immunity might provide opportunities for a delay in or periodic suspension of viral chemotherapy.
Previous therapeutic vaccination trials have generally afforded only limited attention to potential differences in immunogenicity of candidate vaccines or to the definition of patient populations that are optimally responsive to vaccination. It is known that many immune-response parameters, including responses to vaccination, decrease with progression, as assessed by CD4 cell count, of HIV-1 disease. It is also clear that multiple vaccine candidates are available for potential use in therapeutic vaccine trials. AIDS Clinical Trial Group (ACTG) 209 and ACTG 214 were initiated before the era of highly active chemotherapy, in an effort to gain insight into the degree of immune competence required for the induction of cellular immune responses to HIV-1 and to compare several available recombinant HIV-1 envelope vaccines, with respect to tolerability and immunogenicity.
Methods

Study Design
Inclusion and exclusion criteria. ACTGs 209 and 214 enrolled HIV-1-seropositive individuals who were у13 years old. HIV-1 infection was documented by the presence of antibodies to HIV-1, as determined by use of a licensed ELISA. Women of childbearing age were required to have a negative serum or urine human chorionic b-human chorionic gonadotropin within 2 weeks before study entry and to practice adequate birth control, to prevent pregnancy during the study. Exclusion criteria included the following laboratory values: hemoglobin !12 for males or !11 for females; platelet count !75,000/mm 3 ; absolute neutrophil count !1000/mm 3 ; creatinine 11.5 mg/dL; alanine aminotransferase, aspartate aminotransferase, or alkaline phosphatase 15 times the upper limit of normal; and bilirubin 12.5 times the upper limit of normal. Other than patients entering ACTG 209 stratum C (patients with a CD4 cell count !200 cells/mm 3 ), no history of an AIDS-defining opportunistic infection was permitted. No one was allowed to enter the study with active AIDS-defining opportunistic infections. An Epstein-Barr virus (EBV)-transformed B cell line was established for each study participant so that he or she could be randomized and vaccinated.
Entry stratification. Study participants were stratified by baseline CD4 cell counts (table 1) . Individuals with a CD4 cell count у500 cells/mm 3 were eligible for ACTG 214; those with a CD4 cell count of 50-499 cells/mm 3 were eligible for ACTG 209. ACTG 209 study participants were further stratified into groups by baseline CD4 cell counts. Groups A and A1 included those with a CD4 cell count of 350-499 cells/mm3; groups B and C consisted of those with a CD4 cell count of 200-349 and 50-199 cells/mm 3 , respectively. Antiretroviral chemotherapy.
Antiretroviral chemotherapy specified in the protocols was consistent with that in use at the time the trials were planned and conducted (from 1993 through 1995 and before the advent of potent combination regimens, including HIV-1 protease inhibitors). Study participants enrolling in ACTG 214 were not allowed to have used any antiretroviral therapy for the 6 months before the study (table 1) . Study participants in groups A and B of ACTG 209 must have taken zidovudine at a dose of 500-600 mg/day for at least the 2 months immediately before the study but could not have had 112 months of cumulative experience with zidovudine. Patients in group A could not have taken any antiretroviral drug except zidovudine. An open-label, active vaccine pilot subgroup of group A (group A1) was formed to examine the effects of vaccination on patients with a CD4 cell count of 350-500 cells/mm 3 who were not on antiretroviral chemotherapy. Patients in group B could have taken didanosine in the past but could not be taking the drug at study entry. Patients in group C were not governed by the prior antiretroviral eligibility requirement of 2-12 months of zidovudine. During the trial, they were allowed either nucleoside analogue monotherapy or combination therapy with 2 nucleosides, as long as they had been on that therapy for at least 2 months at the time of study entry.
Prior and concomitant medications. Patients receiving any of the following agents at study entry or within 12 weeks of study entry were excluded from the study: agents with immunosuppressive activity (including corticosteroids and chemotherapeutic agents), interferons, other investigational HIV drugs or therapies, parenteral therapies, and prior immunization with HIV-1 components.
Vaccine regimens. Study participants in ACTG 209 were randomized to receive 300 mg of a recombinant MN-based HIV-1 gp120 antigen (MN; Genentech, South San Francisco) that had been adsorbed to aluminum hydroxide (0.6 mg aluminum) with 0.1 mg thimerosal or a matching placebo (table 2) .
Study participants in ACTG 214 were randomized to receive the recombinant MN-based HIV-1 gp120 antigen or one of the following vaccines: 300 mg of a IIIB-based gp120 antigen (IIIB; Genentech) with the same adjuvant; an SF2-based recombinant HIV-1 gp120 antigen (SF2; Chiron, Emeryville, CA) with an MF-59 adjuvant; or an SF2-based nonglycosylated gp120 antigen produced in yeast administered in PBS containing SDS and EDTA (Env 2-3; Chiron). A control group was immunized with either the alum adjuvant or the MF-59 adjuvant. The MF-59 adjuvant is an emulsifier system composed of 0.5% polysorbate 80, 0.5% sorbitan trioleate, and 0.5% squalene as an oil-in-water emulsion. Study participants and personnel were blinded as to whether the immunogen contained HIV-1 env antigen but were aware of the saline or MF-59 randomization because of the different physical appearance of the injection.
In each study, 6 doses of the immunogen or placebo were injected into the deltoid muscle at monthly intervals.
Study centers. The study was conducted at 8 AIDS Clinical Trials Unit sites. All sites, except the University of California, San Francisco (UCSF), performed cellular immune assays on enrolled study participants. Clinical data were collected only for patients enrolled at UCSF. ACTG 209 was terminated before full accrual of the lowest CD4 cell stratum (group C) after an interim analysis that revealed limited immunogenicity of the vaccines tested in this most advanced patient population.
Laboratory Evaluations
Lymphocyte proliferative responses (LPRs) to mitogens and antigens. Tests to determine LPRs to mitogens and antigens were done in quadruplicate by standard techniques. In brief, after isolation by standard ficoll-hypaque centrifugation (Sigma, St. Louis), 10 5 peripheral blood mononuclear cells (PBMC) were suspended in quadruplicate wells of a 96-well plate in 200 mL of RPMI 1640 containing 10% pooled human AB serum and one of the antigens, mitogens, or controls listed in table 3. Stock antigens and mitogens were obtained from a single lot for distribution to each laboratory. A single lot of pooled human AB serum obtained from HIV-1-seronegative donors was used in all lymphoproliferative assays. The serum had been screened for the absence of antigenic activity, using PBMC from healthy HIV-1-seronegative donors, and for the absence of mitogenic activity, using cord blood PBMC. Plates containing working concentrations of all stimulants were made at the laboratories and were stored frozen at Ϫ20ЊC until used. After incubation for 5 days at 37ЊC in 5% CO 2 , 1 mCi of (methyl-3 H)thymidine was added to each well, and cells were harvested 6 h later. H-thymidine incorporation was determined by beta counting.
CTL assays. HIV-1-specific CTL assays were done in triplicate using unstimulated PBMC as effector cells and autologous EBVtransformed B cells induced to express HIV-1 antigens by infection with vaccinia recombinants, as described elsewhere [18, 19] . Vaccinia vectors were used to express HIV-1 env antigens from the IIIB and Plasma HIV-1 RNA assays. Plasma HIV-1 RNA levels were determined in the UCHSC laboratory, using the Roche Monitor assay (Roche Molecular Systems, Branchburg, NJ), which had a lower limit of detection of 200 copies/mL.
Statistical methods. LPR were expressed as both the average cpm and the stimulation index (SI). SIs were determined by dividing the mean cpm for each antigen or mitogen by the mean cpm of the control (designated in table 3). A у5-fold increase in the SI over baseline at both weeks 18 and 22 was defined as a significant change from baseline. The baseline HIV-1 RNA levels for patients with an LPR у5 were compared, using the Wilcoxon rank sum test, with those of vaccine nonresponders. In this analysis, the HIV-1 RNA level for patients with an undetectable level of plasma RNA was arbitrarily set at the assay detection limit (200 copies/mL). HIV-1-specific CTL activity was expressed as the difference between the means of the 51 Cr released by cells infected with vaccinia vectors expressing HIV-1 antigens and that released by cells infected with the b-galactosidase control vaccinia vector. A change in antigen-specific 51 Cr release 15% above baseline was considered a significant change in CTL reactivity. Statistical significance was ascribed to data that reached . P р .05
Results
Safety and tolerability.
One hundred sixty-four subjects were recruited to ACTG 209, and 153 (93%) completed the protocol. One hundred twenty-eight subjects were recruited into ACTG 214, and 114 (89%) completed the study. There were no differences among the treatment assignments in either study with respect to study completion. The active vaccines and adjuvant controls were well tolerated. No study participant discontinued treatment because of protocol-related toxicities. There were no significant changes in CD4 cell counts between the baseline and posttreatment values in any of the strata or for any immunogen in either study (data not shown).
Lymphoproliferative responses as a function of disease stage and baseline plasma HIV-1 RNA level. The immunogenicity of the MN vaccine was studied across 4 strata of CD4 cells in ACTGs 209 and 214. LPR to the antigens and mitogens specified in table 3 were measured twice at baseline (before vaccination) and at weeks 18 and 22 (2 weeks after 5 and 6 vaccinations, respectively). The primary study end point was defined as a у5-fold increase at weeks 18 and 22 in the LPR, to an HIV-1 antigen over the geometric mean titer of the 2 baseline determinations. The immunogenicity of the MN vaccine was generally modest and was restricted to study participants with a CD4 cell count 1350 cells/ mm 3 ( figure 1 ). The primary study end point was seen in 6 (29%) of 21 study participants with a CD4 cell count 1500 cells/mm 3 and receiving the gp120 MN vaccine, in 4 (22%) of 18 stratum A participants (subjects with a CD4 cell count of 350-499 cells/ mm 3 at baseline and receiving antiretroviral chemotherapy), and in 4 (24%) of 17 of stratum A1 participants (subjects with a CD4 cell count of 350-500 cells/mm 3 at baseline and receiving no antiretroviral chemotherapy).
None of 33 patients in stratum B and only 1 stratum C study participant met the primary study end point criterion. No in- creases in the LPR to the gp120 MN antigen were observed in recipients of the alum placebo or the MF-59 placebo. The increased LPR in recipients of the MN immunogen tended to be restricted to the gp120 MN antigen. Although proliferative responses were occasionally seen in other HIV-1 antigens in study participants receiving the gp120 MN vaccine, no increases were seen in non-HIV antigens or to phytohemagglutinin.
Baseline plasma HIV-1 RNA levels were available for patients in ACTG 209. To determine whether there was a relationship between baseline plasma HIV-1 RNA level and vaccine responsiveness, we divided patients into responders and nonresponders on the basis of whether both the week-18 and -22 LPR were above the baseline average by a value у5. Vaccine responders tended to be more likely than nonresponders to have р400 plasma copies of HIV-1 RNA at baseline, although this result did not quite reach statistical significance ( , Wil-P p .067 coxon rank sum test).
Comparative immunogenicity of vaccines in ACTG 214. Immunogenicity of the MN and IIIB and SF2 and Env 2-3 vaccines was compared in individuals with a CD4 cell count 1500 cells/ mm 3 in ACTG 214. LPR in the less-immunosuppressed patient population participating in ACTG 214 was modest. The baseline LPR response in recipients of the IIIB vaccine was similar to that observed for recipients of the MN vaccine (figure 2). LPRs to the gp120 IIIB antigen increased in 6 (29%) of 21 evaluable individuals who received the gp120 IIIB vaccine (table 4) .
LPR to the SF2 and Env 2-3 vaccines were less demonstrable in this patient population; they were elicited in only 1 (5%) of 20 and 2 (10%) of 19 study participants receiving these vaccines, respectively. Recipients of the IIIB vaccine who developed a response to the IIIB envelope in vitro also responded to the MN antigen or the SF2 vaccine (or both) in vitro; however, in most cases, the predominant LPRs was usually restricted to the immunizing antigen. Placebo recipients did not develop novel responses after vaccination. Increased responses to antigens other than the virus envelope and to control (excipient) wells were observed in !5% of study participants in all cases (data not shown).
CTL responses in ACTGs 209 and 214. As shown in figures 3 and 4, the IIIB envelope antigen was the most frequently recognized; a lower percentage of patients manifested HIV-1-specific CTL responses to the MN env or gag antigens. Vaccination with the env antigens used in this study failed to elicit or boost virus-specific CTL responses in any patient, as determined (using the unstimulated PBMC assay) by the presence or absence of CTL to HIV-1 antigens.
Discussion
This linked pair of therapeutic vaccine trials demonstrated only modest immunogenicity of HIV-1 envelope vaccines in the patient populations studied. In general, cellular immune responses to the vaccines administered were restricted to patients with a CD4 cell count 1350 cells/mm 3 . Even in this patient population, the increases in LPR were modest and were observed in a minority of subjects. Using the relatively insensitive, unstimulated PBMC assay to detect HIV-1-specific CTL responses, we found that these vaccines had no demonstrable effect on CTL responses. However, this finding is expected, since antigens were presented to host effector cells as a soluble recombinant protein.
In a small pilot arm of ACTG 209, there was no evidence that zidovudine therapy inhibited the induction of immune responses assessed in this study. The immunogenicity observed with the vaccines used in these trials was generally consistent with that observed in HIV-1-seronegative subjects. Recombinant HIV-1 env vaccines have elicited LPR in some in HIV-1-seronegative persons; however, these immunogens have exhibited a limited ability to elicit HIV-1-specific CTL immunity or antibodies capable of neutralizing primary isolates of HIV-1 [20] [21] [22] [23] [24] [25] .
These studies also demonstrated significant differences in immunogenicity as assessed by LPR to the vaccinating antigen among several available envelope vaccines. In ACTG 214, the MN and IIIB vaccines were more likely to induce novel LPRs than were either of the other vaccines. There was no evidence that MF-59 adjuvant enhanced cellular immune responsiveness. Finally, the studies demonstrated considerable strain specificity with respect to the vaccines used. In every case, when LPR were elicited, they were more frequently seen to the immunizing antigen than to other HIV-1 env antigens studied in vitro. Thus, these studies demonstrate the ability to augment HIV-1-specific immune responses in at least some infected persons.
The results of these studies were initiated before the availability of HIV-1 protease inhibitors and should be interpreted with the knowledge that study participants were not receiving fully suppressive antiretroviral therapy. Thus, any observed increases in cellular immune responses to HIV-1 env antigens were generated in the context of ongoing viral replication in most patients. Indeed, we demonstrated an inverse correlation between the baseline plasma HIV-1 RNA level and our ability to elicit new cellular immune responses. Over the past 3 years, increasing evidence has accumulated that demonstrate cumu- lative improvements in a number of cellular and humoral immune response parameters in association with successful sustained suppression of viral replication [15, 16] . In view of the immune restoration exhibited by individuals in whom HIV-1 replication is more completely suppressed by highly active antiretroviral chemotherapy, there is renewed interest in studies of therapeutic vaccination. Preliminary studies suggest that greater increases in HIV-1 LPR can be generated by immunization of patients who are receiving more active antiretroviral regimens [17] .
ACTG studies 209 and 214 lend insight into the design of future therapeutic vaccine trials. First, it is clear that cellular immune responses are differentially induced as a function of disease stage. Thus, if the premise of a therapeutic vaccine trial is that induction of cell-mediated immune responses might serve to help prevent resumption of viral replication, pilot studies should be conducted with the specific vaccines and adjuvants to be included in the vaccine trial, to identify patient populations in which putatively beneficial immune responses can be predictably induced. From these studies, it is apparent that immunogenicity of therapeutic HIV-1 vaccine candidates in infected persons is probably maximal in early disease. Second, it is clear that not all vaccines are equal in their immunogenicity. Because of the expense of large clinical trials, it would seem prudent to assess comparative immunogenicity of available vaccine candidates in the appropriate patient populations before a definitive study. Finally, at least in the case of the envelope vaccines used in these studies, considerable strain specificity was observed. If the hypothesis of a therapeutic vaccine trial is that the immunogen(s) used will help the host contain viral replication, all things considered, vaccines that induce more cross-reactive immune responses might be expected to offer more immunologic pressure directed at autologous virus. This last issue could be less relevant in the case of more immunogenic vaccines or if the immunogen is composed of more conserved portions of the virus, such as gag or nef antigens.
Whether therapeutic vaccination will play a meaningful role in HIV-1 therapeutics remains an open question. Several factors have changed since the initiation of ACTG 209 and ACTG 214. The immune restoration associated with virus suppression and the potential ability to protect antigen-specific T cells activated by immunization from viral infection provide the possibility that vaccines will induce more potent HIV-1-specific immune responses [8, 17] . In addition, more robust tools for the assessment of HIV-1-specific cellular immune responses are now available [26, 27] . Finally, a number of novel vaccine approaches have emerged that might serve as more effective immunogens [28, 29] . These developments coupled with more sensitive tools for assessing HIV-1 replication in vivo suggest that further carefully designed therapeutic vaccination studies might provide useful insights into the role of virus-specific host responses in controlling HIV-1 replication in vivo, as well as guidance in the development of vaccines directed at the prevention of HIV-1 transmission.
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